DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Nesvacumab
Nesvacumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
The Angiopoietin-2 and TIE Pathway As a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer
The Two Tontti Tudiul Lui Hi Ha Unit
Aflibercept and Ang1 Supplementation Improve Neoadjuvant Or Adjuvant
(INN) for Biological and Biotechnological Substances
(Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
NOVEL TREATMENT STRATEGIES for DIABETIC EYE DISEASE Next-Generation Anti–VEGF-A Drugs and Combination Agents Show Potential
Phase 2 RUBY Trial
REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors Kyriakos P
(INN) for Biological and Biotechnological Substances
Therapeutic Targeting of the Angiopoietin–TIE Pathway
Strategies to Obtain Diverse and Specific Human Monoclonal
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Top View
WO 2019/028191 Al 07 February 2019 (07.02.2019) W !P O PCT
WO 2016/073894 Al 12 May 2016 (12.05.2016) W P O P CT
New Pharmacotherapies for Diabetic Retinopathy
Newly Diagnosed Glioblastoma
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
The Evolving Treatment of Diabetic Retinopathy
International Nonproprietary Names for Pharmaceutical Substances (INN)
Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
WO 2015/038782 Al 19 March 2015 (19.03.2015) P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
What Does 2018 Hold for the Pharma Industry?
(19) United States Mar. 12, 2015
WO 2015/038818 A2 19 March 2015 (19.03.2015) P O P C T
View Annual Report
2016 Medicines in Development for Diabetes and Related Conditions
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT